José Wagner Leonel Tavares-Júnior, Gabriella Cunha Vieira Ciurleo, Alissa Moura Formiga, Thais de Maria Frota Vasconcelos, Marcello Holanda de Andrade, Werbety Lucas Queiroz Feitosa, Antônio Alves Sobreira-Neto, Chiara Gübel Portugal, Lorenzo Marinho Morais, Samuel Cavalcante Marinho, Emanuel de Assis Bertulino Martins Gomes, Esther de Alencar Araripe Falcão Feitosa, Emmanuelle Silva Tavares Sobreira, Reinaldo Barreto Oriá, Manoel Alves Sobreira-Neto, and Pedro Braga-Neto
ABSTRACT. Infection with the SARS-CoV-2 virus can lead to neurological symptoms in the acute phase and in the Long COVID phase. These symptoms usually involve cognition, sleep, smell disorders, psychiatric manifestations, headache and others. This condition is more commonly described in young adults and women. This symptomatology can follow severe or mild cases of the disease. The importance of this issue resides in the high prevalence of neurological symptoms in the Long COVID phase, which entails significant morbidity in this population. In addition, such a condition is associated with high health care costs, with some estimates hovering around 3.7 trillion US dollars. In this review, we will sequentially describe the current knowledge about the most prevalent neurological symptoms in Long COVID, as well as their pathophysiology and possible biomarkers.